The purpose of the Medtronic SEEQ™ Performance study is to build further evidence on the clinical and economic benefit of the Medtronic market-released SEEQ™ Mobile Cardiac Telemetry System/External Cardiac Monitor System (MCT/ECM).

Inclusion Criteria:

• Patient is indicated for a SEEQ™ MCT/ECM System for approved indications
• Patient is 18 years of age or older
• Patient is willing and able to provide consent and authorize the use and disclosure of health information
• Patient is willing and able to comply with the protocol

Exclusion Criteria:

• Patient has known allergy and/or hypersensitivity to adhesives or hydrogel.
• Patient has suspected potential life-threatening arrhythmias, or requires in-subject/in-hospital monitoring.
• Patient will undergo a medical procedure that would preclude full participate during the prescribed duration of the SEEQ™
• Patient has an implanted cardiac device, (e.g., pacemaker, Implantable Cardioverter Defibrillator, Cardiac Resynchronization Therapy)

Patients who require monitoring for the detection of non-lethal cardiac arrhythmias such as, but not limited to, supraventricular tachycardias (for example, atrial fibrillation, atrial flutter, paroxysmal SVTs), ventricular ectopy, bradyarrhythmias, and conduction disorders.